This is a paid advertisement for legal services. Sponsor and responsible law firm: JAG Legal Group, using the 1-800-LAW-FIRM brand.

Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor’s advice can result in injury or death. Consult your physician before making any decision regarding prescribed medication or medical treatment.

Gabapentin and pregabalin remain FDA-approved for their approved indications. This advertisement is not an FDA notice or a product recall. Research findings do not establish that a medicine caused an individual injury. Jurisdiction and representation disclosures.

LEGAL INFORMATION FOR PATIENTS & FAMILIES Attorney advertising · JAG Legal Group
RESEARCH & SAFETY

Gabapentin label dates: a recent posting is not always a new warning

Understand the difference between a label posting date, a revision date and an FDA action before interpreting a safety headline.

JAG Legal Group · Published November 2, 2026

Published November 2, 2026 · Historical safety information explained

Three dates can describe different events

A medicine webpage can be updated without a newly discovered risk. For example, the ScieGen gabapentin label on DailyMed shows an October 23, 2026 update and a July 2026 revision date, while its recent-major-changes table identifies April 2025 warning changes. Those dates alone do not demonstrate a new October dementia warning.

Check the underlying FDA record

The Drugs@FDA Neurontin capsule approval history lists an April 25, 2025 labeling action. The linked April 2025 prescribing information addresses risks with rapid discontinuation, including seizures, withdrawal symptoms and observed suicidal behavior or thoughts after discontinuation. This is historical labeling, not a newly issued November 2026 alert.

Breathing warnings have their own history

The FDA breathing-risk communication was posted December 19, 2019. It concerns both gabapentin products and the distinct medicine pregabalin, particularly with opioids, other central nervous system depressants or underlying respiratory impairment. A recent article discussing that communication does not make it a new warning. See our breathing-risk guide.

Keep the information supplied with your prescription

Retain the medication guide, pharmacy label and dispensing dates if available. For a legal review, the warnings supplied during your treatment matter alongside the medical record. Do not change or stop prescribed treatment based on a headline. Ask your prescriber about concerns, and see our withdrawal guide for safety context. A label warning does not itself establish liability or an entitlement to compensation.

YOUR NEXT STEP

You don’t have to sort
through this alone.

Talk through your concerns and learn what information a legal review may require.

Call 1-800-LAW-FIRM ↗

1-800-529-3476 · No obligation to retain a lawyer

Request a reviewCall 1-800-LAW-FIRM ↗